Einzeltreffer — DigiBib

Computation promises to accelerate, de-risk and optimize drug research and development. An increasing number of companies have entered this space, specializing in the design of new algorithms, computing on proprietary data, and/or development of hardware to improve distinct drug pipeline stages. The large number of such companies and their unique strategies and deals have created a highly complex and competitive industry. We comprehensively analyze the companies in this space to highlight trends and opportunities, identifying highly occupied areas of risk and currently underrepresented niches of high value.

Titel:	Characterizing emerging companies in computational drug development.
Autor/in / Beteiligte Person:	Markey, C ; Croset, S ; Woolley, OR ; Buldun, CM ; Koch, C ; Koller, D ; Reker, D
Zeitschrift:	Nature computational science, Jg. 4 (2024-02-01), Heft 2, S. 96-103
Veröffentlichung:	[New York, N.Y.] : Springer Nature, [2021]-, 2024
Medientyp:	academicJournal
ISSN:	2662-8457 (electronic)
DOI:	10.1038/s43588-024-00594-8
Schlagwort:	Drug Development Drug Industry Algorithms
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Review Language: English [Nat Comput Sci] 2024 Feb; Vol. 4 (2), pp. 96-103. <i>Date of Electronic Publication: </i>2024 Feb 26. MeSH Terms: Drug Industry* ; Algorithms* ; Drug Development References: Brown, N. et al. Artificial intelligence in chemistry and drug design. J. Comput. Aided Mol. Des. 34, 709–715 (2020). (PMID: 10.1007/s10822-020-00317-x32468207) ; Kopp, E. BioXCel Therapeutics announces FDA approval of IGALMI™ (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel Therapeutics (6 April 2022). ; Savage, N. Drug discovery companies are customizing ChatGPT: here’s how. Nat. Biotechnol. 41, 585–586 (2023). (PMID: 10.1038/s41587-023-01788-737095351) ; Joachim, B., Rehm, W., Ryan, S. & Wright, P. A biotech survival kit for a challenging public-market environment. McKinsey (19 September 2022). ; Leclerc, O., Suhendra, M. & The, L. What are the biotech investment themes that will shape the industry? McKinsey (10 June 2022). ; Hodgson, J. 2022—toughing out the trough. Nat. Biotechnol. 41, 159–173 (2023). (PMID: 10.1038/s41587-023-01661-7) ; Prieto-Martínez, F. D., López-López, E., Juárez-Mercado, K. E. & Medina-Franco, J. L. in In Silico Drug Design (ed. Roy, K.) 19–44 (Academic, 2019). ; Mayr, A. et al. Large-scale comparison of machine learning methods for drug target prediction on ChEMBL. Chem. Sci. 9, 5441–5451 (2018). (PMID: 10.1039/C8SC00148K301552346011237) ; Zhu, H. Big data and artificial intelligence modeling for drug discovery. Annu. Rev. Pharmacol. Toxicol. 60, 573–589 (2020). (PMID: 10.1146/annurev-pharmtox-010919-02332431518513) ; Borhani, D. W. & Shaw, D. E. The future of molecular dynamics simulations in drug discovery. J. Comput. Aided Mol. Des. 26, 15–26 (2012). ; Modulus discovery closes $20.4M USD Series C. Modulus (1 March 2022). ; Jarvis, L. M. Relay Therapeutics launches to tackle protein movement. Chemical & Engineering News (14 September 2016). ; Bell, J. Gilead taps into machine learning to find new NASH drugs. BioPharma Dive (16 April 2019). ; Chory, E. J., Gretton, D. W., DeBenedictis, E. A. & Esvelt, K. M. Enabling high-throughput biology with flexible open-source automation. Mol. Syst. Biol. 17, e9942 (2021). (PMID: 10.15252/msb.20209942337646807993322) ; Ma, C., Peng, Y., Li, H. & Chen, W. Organ-on-a-chip: a new paradigm for drug development. Trends Pharmacol. Sci. 42, 119–133 (2021). (PMID: 10.1016/j.tips.2020.11.00933341248) ; Reker, D. Practical considerations for active machine learning in drug discovery. Drug Discov. Today Technol. 32/33, 73–79 (2019). (PMID: 10.1016/j.ddtec.2020.06.00133386097) ; Wadman, M. FDA no longer needs to require animal tests before human drug trials. Science 379, 127–128 (2023). (PMID: 10.1126/science.adg627636634170) ; Hemmerich, J. & Ecker, G. F. In silico toxicology: from structure–activity relationships towards deep learning and adverse outcome pathways. Wiley Interdiscip. Rev. Comput. Mol. Sci. 10, e1475 (2020). (PMID: 10.1002/wcms.1475358661389286356) ; Baig, M. H. et al. Computer aided drug design: successes and limitations. Curr. Pharm. Des. 22, 572–581 (2016). (PMID: 10.2174/138161282266615112500055026601966) ; Bhardwaj, A. et al. Open source drug discovery—a new paradigm of collaborative research in tuberculosis drug development. Tuberculosis 91, 479–486 (2011). (PMID: 21782516) ; Weingarten, M. D. E. Shaw Research licenses first-in-class therapeutic for immunological diseases to Lilly. D. E. Shaw Research (13 June 2022). ; Hale, C. Schrödinger’s in-house pipeline helps fetch $2.7B molecule discovery deal with BMS. Fierce Biotech (18 January 2020). ; Olleros, F.-J. Emerging industries and the burnout of pioneers. J. Prod. Innov. Manag. 3, 5–18 (1986). (PMID: 10.1111/1540-5885.310005) ; Pagano, M., Panetta, F. & Zingales, L. Why do companies go public? An empirical analysis. J. Financ. 53, 27–64 (2002). (PMID: 10.1111/0022-1082.25448) ; Eboli, M., Ozel, B., Teglio, A. & Toto, A. Connectivity, centralisation and ‘robustness-yet-fragility’ of interbank networks. Ann. Finance 19, 169–200 (2022). ; Alexander, C. M. et al. Trends and perspectives of biological drug approvals by the FDA: a review from 2015 to 2021. Biomedicines 10, 2325 (2022). (PMID: 10.3390/biomedicines10092325) ; Madura Jayatunga, L. B., Ludwig, R., Schulze, U. & Meier, C. in In Vivo (Pharma Intelligence, 2022). ; Lajoie, J. M. & Shusta, E. V. Targeting receptor-mediated transport for delivery of biologics across the blood–brain barrier. Annu. Rev. Pharmacol. Toxicol. 55, 613–631 (2015). (PMID: 10.1146/annurev-pharmtox-010814-12485225340933) ; Bender, A. & Cortés-Ciriano, I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug Discov. Today 26, 511–524 (2021). (PMID: 10.1016/j.drudis.2020.12.00933346134) ; Eisenstein, M. Active machine learning helps drug hunters tackle biology. Nat. Biotechnol. 38, 512–514 (2020). (PMID: 10.1038/s41587-020-0521-432393920) ; AlphaFold and beyond. Nat. Methods 20, 163 (2023). ; Markey, C. & Croset, S. ComputationalDrugRD. Zenodo https://doi.org/10.5281/zenodo.10482006 (2024). Entry Date(s): Date Created: 20240227 Date Completed: 20240229 Latest Revision: 20240607 Update Code: 20240607

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Characterizing emerging companies in computational drug development.